{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:04:45Z","timestamp":1786133085884,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:p>\n                    Within monocytes, 1,25-dihydroxyvitamin D [1,25(OH)\n                    <jats:sub>2<\/jats:sub>\n                    D] is important for production of cathelicidins, which in turn, are critical for antibacterial action. Fibroblast growth factor 23 (FGF23) decreases 1,25(OH)\n                    <jats:sub>2<\/jats:sub>\n                    D production and thus, could increase infection risk. We examined this possibility in 3141 community-dwelling adults ages \u226565 years old at baseline in the Cardiovascular Health Study using Cox proportional hazards models to examine the association between FGF23 concentrations and first infection-related hospitalizations and determine whether associations differed by the presence of CKD (eGFR&lt;60 ml\/min per 1.73 m\n                    <jats:sup>2<\/jats:sup>\n                    [\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    =832] or urine albumin-to-creatinine ratio &gt;30 mg\/g [\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    =577]). Mean\u00b1SD age of participants was 78\u00b15 years old, 60% of participants were women, and the median plasma FGF23 concentration was 70 (interquartile range, 53\u201399) relative units per milliliter. In fully adjusted models, higher FGF23 concentrations associated with higher risk of first infection-related hospitalization (hazard ratio [HR], 1.11; 95% confidence interval [95% CI], 1.03 to 1.20 per doubling of FGF23) during a median follow-up of 8.6 years. In participants with or without CKD (defined by eGFR), FGF23 concentration associated with first infection-related hospitalization with HRs of 1.24 (95% CI, 1.08 to 1.42) and 1.06 (95% CI, 0.97 to 1.17) per doubling of FGF23, respectively (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.13 for interaction). Associations did not differ between groups when stratified by urine albumin-to-creatinine ratio. In sensitivity analyses, the addition of serum calcium, phosphorus, 25-hydroxyvitamin D, intact parathyroid hormone, and 24,25-dihydroxyvitamin D did not meaningfully change the estimates. In conclusion, in community-dwelling older adults, higher plasma FGF23 concentrations independently associated with the risk of first infection-related hospitalization.\n                  <\/jats:p>","DOI":"10.1681\/asn.2016040401","type":"journal-article","created":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T07:58:36Z","timestamp":1478851116000},"page":"1239-1246","source":"Crossref","is-referenced-by-count":28,"title":["Fibroblast Growth Factor 23 and the Risk of Infection-Related Hospitalization in Older Adults"],"prefix":"10.1681","volume":"28","author":[{"given":"Kristen L.","family":"Nowak","sequence":"first","affiliation":[{"name":"Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci M.","family":"Bartz","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorien","family":"Dalrymple","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, Davis, Sacramento, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Kidney Research Institute, University of Washington, Seattle, Washington;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Kestenbaum","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Kidney Research Institute, University of Washington, Seattle, Washington;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Shlipak","sequence":"additional","affiliation":[{"name":"Medicine and"},{"name":"Epidemiology and Biostatistics, University of California, San Francisco, California;"},{"name":"General Internal Medicine Section, San Francisco Veterans Affairs Medical Center, San Francisco, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav S.","family":"Garimella","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Tufts Medical Center, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim H.","family":"Ix","sequence":"additional","affiliation":[{"name":"Nephrology and"},{"name":"Preventative Medicine, University of California, San Diego, California; and"},{"name":"Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Chonchol","sequence":"additional","affiliation":[{"name":"Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Campus, Aurora, Colorado;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,11,10]]},"reference":[{"key":"B1-20230829","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1525-139X.2007.00308.x","article-title":"Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease.","volume":"20","author":"Stubbs","year":"2007","journal-title":"Semin Dial"},{"key":"B2-20230829","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1074\/jbc.M408903200","article-title":"Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo.","volume":"280","author":"Saito","year":"2005","journal-title":"J Biol Chem"},{"key":"B3-20230829","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jacc.2012.03.040","article-title":"Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).","volume":"60","author":"Ix","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"B4-20230829","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis.","volume":"22","author":"Kendrick","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B5-20230829","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"},{"key":"B6-20230829","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"B7-20230829","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1001\/archinte.165.21.2514","article-title":"Infectious disease hospitalizations among older adults in the United States from 1990 through 2002.","volume":"165","author":"Curns","year":"2005","journal-title":"Arch Intern Med"},{"key":"B8-20230829","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1532-5415.2008.01712.x","article-title":"Hospital charges attributable to a primary diagnosis of infectious diseases in older adults in the United States, 1998 to 2004.","volume":"56","author":"Curns","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"B9-20230829","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1053\/j.ajkd.2011.07.012","article-title":"The risk of infection-related hospitalization with decreased kidney function.","volume":"59","author":"Dalrymple","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B10-20230829","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1681\/ASN.2014101009","article-title":"Low vitamin D and High fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO Study.","volume":"27","author":"Chonchol","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B11-20230829","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00467-012-2336-0","article-title":"Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?","volume":"28","author":"Bacchetta","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"B12-20230829","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1172\/JCI83470","article-title":"FGF23 signaling impairs neutrophil recruitment and host defense during CKD.","volume":"126","author":"Rossaint","year":"2016","journal-title":"J Clin Invest"},{"key":"B13-20230829","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ackd.2006.04.004","article-title":"Infectious complications in chronic kidney disease.","volume":"13","author":"Naqvi","year":"2006","journal-title":"Adv Chronic Kidney Dis"},{"key":"B14-20230829","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2215\/CJN.01290308","article-title":"Epidemiology of acute infections among patients with chronic kidney disease.","volume":"3","author":"Dalrymple","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B15-20230829","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/archinternmed.2008.560","article-title":"Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey.","volume":"169","author":"Ginde","year":"2009","journal-title":"Arch Intern Med"},{"issue":"Suppl 2","key":"B16-20230829","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1111\/j.1753-4887.2008.00096.x","article-title":"Regulation of vitamin D homeostasis: Implications for the immune system.","volume":"66","author":"van Etten","year":"2008","journal-title":"Nutr Rev"},{"key":"B17-20230829","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1126\/science.1123933","article-title":"Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.","volume":"311","author":"Liu","year":"2006","journal-title":"Science"},{"key":"B18-20230829","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1479-5876-7-28","article-title":"Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis.","volume":"7","author":"Jeng","year":"2009","journal-title":"J Transl Med"},{"key":"B19-20230829","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2013.09.002","article-title":"Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.","volume":"231","author":"Jovanovich","year":"2013","journal-title":"Atherosclerosis"},{"key":"B20-20230829","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1681\/ASN.2007010068","article-title":"How fibroblast growth factor 23 works.","volume":"18","author":"Liu","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B21-20230829","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.ajkd.2014.02.015","article-title":"Estimated GFR and circulating 24,25-dihydroxyvitamin D3 concentration: A participant-level analysis of 5 cohort studies and clinical trials.","volume":"64","author":"de Boer","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B22-20230829","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/ki.2012.193","article-title":"The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease.","volume":"82","author":"Bosworth","year":"2012","journal-title":"Kidney Int"},{"key":"B23-20230829","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1373\/clinchem.2015.240051","article-title":"24,25-Dihydroxyvitamin d3 and vitamin D status of community-dwelling black and white Americans.","volume":"61","author":"Berg","year":"2015","journal-title":"Clin Chem"},{"key":"B24-20230829","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/1047-2797(91)90005-W","article-title":"The Cardiovascular Health Study: Design and rationale.","volume":"1","author":"Fried","year":"1991","journal-title":"Ann Epidemiol"},{"key":"B25-20230829","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"key":"B26-20230829","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa043161","article-title":"Cystatin C and the risk of death and cardiovascular events among elderly persons.","volume":"352","author":"Shlipak","year":"2005","journal-title":"N Engl J Med"},{"key":"B27-20230829","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/j.ajkd.2007.11.018","article-title":"Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD.","volume":"51","author":"Stevens","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"B28-20230829","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.293.14.1737","article-title":"Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors.","volume":"293","author":"Shlipak","year":"2005","journal-title":"JAMA"},{"key":"B29-20230829","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.113.005499","article-title":"Fibroblast growth factor-23 and incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS).","volume":"130","author":"Mathew","year":"2014","journal-title":"Circulation"},{"key":"B30-20230829","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline.","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201704000-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:28:26Z","timestamp":1786130906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201704000-00026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2016040401","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,10]]}}}